Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. 483
  6. /
  7. Stanley Specialty Pharmacy Compounding and Wellness Center
483
•Stanley Specialty Pharmacy Compounding and Wellness Center•July 7, 2016

Stanley Specialty Pharmacy Compounding and Wellness Center – FDA 483, Jul 7, 2016

Record Details

Stanley Specialty Pharmacy Compounding and Wellness Center received an FDA Form 483 following an inspection conducted from June 6 to July 7, 2016. The inspection revealed several significant observations related to the firm's sterile drug production processes, indicating a need for improved quality control and adherence to established manufacturing standards.

Key observations included a deficient system for monitoring environmental conditions within aseptic processing areas. The firm was found not to conduct environmental or personnel monitoring during or after sterile operations, and viable surface monitoring was performed infrequently. Additionally, protective apparel worn by employees was inadequate, with operators exhibiting exposed skin on their neck, face, and forehead while working in critical ISO 5 laminar air flow hoods, and sterile gowning was not utilized.

The FDA also noted that procedures intended to prevent microbiological contamination of sterile drug products lacked validation of the sterilization process. Specifically, media fills did not accurately simulate actual production or incorporate the most challenging conditions to ensure reproducibility and prevent contamination. Furthermore, the cleaning and disinfection system for aseptic processing areas was found deficient, as the firm used a sporicidal agent without scientific data to support its concentration and contact time for effective disinfection.

These observations highlight areas where the company needs to implement corrective actions to ensure the safety, quality, and sterility of its drug products, aligning its practices with appropriate manufacturing guidelines. The firm is expected to address these findings to demonstrate compliance with regulatory expectations for sterile drug production.

Company
Stanley Specialty Pharmacy Compounding and Wellness Center
Inspection date
July 7, 2016
Product type
Drugs
Office
Atlanta District Office
Person
  • Bonita S. Chester (Director of Inspection Readiness)
View Company Profile

ID · ef328bd0-ca3e-48a6-b431-0e418267d1a0

Violation Codes1
21 CFR 331(c)

Full citation text and observation details available on the Dashboard.

Other documents for Stanley Specialty Pharmacy Compounding and Wellness Center
  • 483 - 2021-10-01October 1, 2021
  • 483 - 2017-08-04August 4, 2017

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Stanley Specialty Pharmacy Compounding and Wellness Center
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.